Summary & Overview
HCPCS A9594: Gallium Ga-68 PSMA-11 Diagnostic PET, 1 mCi
HCPCS Level II code A9594 denotes a single 1 millicurie dose of Gallium Ga-68 PSMA-11 for diagnostic PET imaging, a radiopharmaceutical used to localize prostate cancer via PSMA-targeted imaging. Nationally, PSMA PET tracers have grown in clinical importance for staging, recurrence detection, and guiding management in prostate cancer patients, making accurate coding and coverage understanding essential for providers and payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns and typical reimbursement contexts (where available), clinical context for use of the tracer in PET imaging, and the operational aspects relevant to billing a radiopharmaceutical dose. The publication also outlines common modifiers associated with services of this type and notes where input data were not provided.
This summary equips billing managers, radiology administrators, and policy analysts with a concise reference to the clinical purpose of A9594, the service settings where it is typically administered, and the payer landscape addressed in the accompanying sections.
Billing Code Overview
HCPCS Level II code A9594 describes Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 millicurie. This code represents a radiopharmaceutical dose of Gallium Ga-68 PSMA-11 used for diagnostic PET imaging targeting prostate-specific membrane antigen (PSMA), commonly utilized in the evaluation of prostate cancer.
-
Service type: Diagnostic radiopharmaceutical administration for PET imaging
-
Typical site of service: Outpatient imaging centers, hospital outpatient departments, and nuclear medicine or PET suites
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with biochemical recurrence of prostate cancer following radical prostatectomy is referred for a targeted prostate-specific membrane antigen (PSMA) PET scan using Gallium Ga-68 PSMA-11 (billing code A9594) to localize sites of recurrent disease. The clinical workflow begins with ordering by a urologist or medical oncologist, documentation of the indication (rising prostate-specific antigen), and scheduling with a nuclear medicine or radiology outpatient PET/CT facility. On the day of service, the radiopharmacy prepares a 1 millicurie dose of Gallium Ga-68 PSMA-11 under sterile radiopharmaceutical handling protocols. The patient arrives fasting per site protocol, IV access is obtained, and the tracer is administered intravenously. After an uptake period (typically 45–60 minutes), the patient undergoes whole-body PET/CT imaging. The interpreting nuclear medicine physician reviews images, generates a diagnostic report describing PSMA-avid lesions, and communicates results to the referring provider for treatment planning (e.g., salvage radiotherapy, systemic therapy, or metastasis-directed therapy). Typical sites of service include outpatient hospital-based nuclear medicine departments, freestanding imaging centers, and academic medical centers. Typical providers involved are nuclear medicine physicians, radiopharmacists, PET technologists, and referring urologists or medical oncologists. Common clinical scenarios include localization of recurrent prostate cancer with low but rising PSA levels, staging in high-risk prostate cancer, and evaluation of suspected oligometastatic disease for targeted interventions.
Coding Specifications
| Modifier | Description |
|---|